Thomas Caligiuri, MD
Nephrology · Fort Worth, TXNPI 1407318470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,769 and has fallen 69.1% since, to $547 in 2025.
Across 130 payments — averaging $33.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$841
- Otsuka America Pharmaceutical, Inc.$427
- Travere Therapeutics, Inc.$425
- Medtronic$287
- Mallinckrodt Hospital Products Inc.$276
- GSK$259
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,12595%
- Education$2175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 20 | $841 |
| Otsuka America Pharmaceutical, Inc. | 11 | $427 |
| Travere Therapeutics, Inc. | 10 | $425 |
| Medtronic | 3 | $287 |
| Mallinckrodt Hospital Products Inc. | 13 | $276 |
| GSK | 5 | $259 |
| Fresenius USA Marketing, Inc. | 12 | $250 |
| Daiichi Sankyo Inc. | 11 | $244 |
| Nxstage Medical, Inc. | 5 | $240 |
| Calliditas Therapeutics US Inc. | 7 | $227 |
| Penumbra, Inc. | 1 | $137 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $107 |
| Novartis | 4 | $98 |
| OPKO Pharmaceuticals, LLC | 6 | $97 |
| Bayer | 4 | $71 |
| Aurinia Pharma U.S., Inc. | 3 | $67 |
| Amgen | 2 | $47 |
| Vifor Pharma, Inc. | 2 | $46 |
| Mozarc Medical US LLC | 2 | $32 |
| Sanofi | 1 | $30 |
| Tactile Systems Technology Inc | 1 | $27 |
| Ardelyx, Inc. | 1 | $26 |
| Akebia Therapeutics Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Merck | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$255
- JYNARQUE$227
- NXSTAGE SYSTEM ONE$150
- NXSTAGE PUREFLOW SOLUTION$150
- Penumbra System$137
- ELLIPSYS VASCULAR ACCESS SYSTEM$130
- IN.PACT AV$126
- INJECTAFER$125
- TARPEYO$125
- FARXIGA$125
How this compares
$4,342 in reported general payments places this provider in the 70th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nifedipine ErNifedipine | 31 | $768 |
| Chlorthalidone | 17 | $351 |
| Losartan Potassium | 31 | $167 |
| Carvedilol | 20 | $155 |
| Spironolactone | 29 | $121 |
| Lisinopril | 19 | $111 |
| Amlodipine Besylate | 17 | $82 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Fort Worth
- Saravanan BalamuthusamyFort Worth$435K
- Sandeep ShoriFort Worth$195K
- Michael AragonFort Worth$138K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.